Cited by 124Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

Microglial VEGF Receptor Response Is an Integral Chemotactic Component in Alzheimer's Disease Pathology

Open access
Ryu, Jae K., Cho, Taesup, Choi, Hyun B., Wang, Yu Tian, McLarnon, James G.·2009·The Journal of Neuroscience

Abstract

We hypothesize that microglial chemotactic responses to amyloid-β peptide (Aβ 1–42) serve as an early and integral component of inflammatory response in Alzheimer's disease (AD) brain. This study reports a receptor for vascular endothelial growth factor (VEGF), termed VEGF-1 (Flt-1), subserves microglial chemotactic responses induced by Aβ 1–42 stimulation,in vivo and in vitro. Expression of Flt-1 was significantly increased in tissue obtained from AD patients [compared with tissue from nondemented (ND) individuals], in Aβ 1–42-injected rat hippocampus, and in peptide-stimulated human microglia. Single and double immunohistochemical staining demonstrated marked immunoreactivity, for both Flt-1 and its ligand VEGF, in association with microglia and Aβ deposits in AD, but not ND, brain tissue. Functionally, treatment with anti-Flt-1 antibody was highly effective in inhibiting microglial mobility and chemotactic responses measured in vitro using a transwell migration assay.In vivo, transplanted enhanced green fluorescent protein (EGFP)-labeled microglia exhibited Flt-1-dependent chemotaxis induced by peptide injection with anti-Flt-1 effective in blocking migration of cells. Importantly, anti-Flt-1 reduction of microglial mobility was neuroprotective in peptide-injected hippocampus and associated with a significant increase in numbers of viable hippocampal neurons. The results of this study suggest critical functional roles for Flt-1 in mediating microglial chemotactic inflammatory responses which contribute to pathological conditions in AD brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.2888-08.2009

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Upregulation of Flt-1 has been observed in the entorhinal cortical sections from human AD brain and in human microglia cells following treatment with Aβ42.

    “Interestingly, upregulation of Flt-1 has been observed in the entorhinal cortical sections from human AD brain and in human microglia cells following treatment with Aβ42.36”
  • VEGF and its receptor Flt-1 are implicated in the microglial chemotactic response to Aβ deposits.

    “The growth factor VEGF, along with its receptor Flt-1, which is expressed on microglia, has also been implicated in the microglial chemotactic response to Aβ deposits through both in vitro and in vivo experiments [86].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ryu, J. K., Cho, T., Choi, H. B., Wang, Y. T., & McLarnon, J. G.
Affiliations
University of British Columbia (CA)
Corresponding author
McLarnon, James G.
Venue
The Journal of Neuroscience
Published
2009-01-07
Volume
29
Issue
1
Pages
3-13
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2022811766
Cited by
121
References
45
Citations by year
2026: 5 · 2025: 4 · 2024: 12 · 2023: 10 · 2022: 4 · 2021: 9 · 2020: 6 · 2019: 6 · 2018: 9 · 2017: 4 · 2016: 1 · 2015: 9 · 2014: 6 · 2013: 13 · 2012: 8
FWCI
4.91
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association
  • Fondation pour la Recherche sur Alzheimer
  • Department of Psychiatry, Faculty of Medicine, University of British Columbia
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
Alzheimer's disease, microglia, amyloid-beta, microglial chemotaxis, neuroinflammation, microglial migration, neuroprotection, hippocampus, amyloid-beta deposition
MeSH terms
Adult, Aged, Aged, 80 and over, Alzheimer Disease, Analysis of Variance, Animals, Cell Movement, Cells, Cultured, Disease Models, Animal, Glial Fibrillary Acidic Protein, Hippocampus, HLA-DR Antigens, Humans, Mice, Transgenic, Middle Aged, Peptide Fragments, Phosphopyruvate Hydratase, Postmortem Changes, RNA, Messenger, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Rats, Sprague-Dawley, Microglia, Entorhinal Cortex, CD11b Antigen, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor-1, Green Fluorescent Proteins, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review